Stryker Beats on Revenue, Matches Expectations on EPS
Stryker (NYS: SYK) reported earnings on April 17. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Stryker beat expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue improved and GAAP earnings per share increased significantly.
Gross margins contracted, operating margins dropped, net margins grew.
Stryker reported revenue of $2.16 billion. The 22 analysts polled by S&P Capital IQ predicted revenue of $2.12 billion on the same basis. GAAP reported sales were 7.2% higher than the prior-year quarter's $2.02 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.99. The 26 earnings estimates compiled by S&P Capital IQ predicted $0.99 per share on the same basis. GAAP EPS of $0.91 for Q1 were 17% higher than the prior-year quarter's $0.78 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 67.2%, 130 basis points worse than the prior-year quarter. Operating margin was 22.7%, 160 basis points worse than the prior-year quarter. Net margin was 16.2%, 90 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $2.13 billion. On the bottom line, the average EPS estimate is $0.99.
Next year's average estimate for revenue is $8.69 billion. The average EPS estimate is $4.11.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,448 members out of 1,478 rating the stock outperform, and 30 members rating it underperform. Among 433 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 424 give Stryker a green thumbs-up, and nine give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Stryker is outperform, with an average price target of $61.02.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Stryker the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Stryker to My Watchlist.
At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Motley Fool newsletter services have recommended buying shares of Stryker. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.